The U.S. Court of Appeals for the Fifth Circuit issued a ruling on Wednesday rejecting a legal challenge brought by PhRMA, the pharmaceutical industry's primary trade group. The lawsuit aimed to dismantle the Medicare drug price negotiation program, a key component of the Inflation Reduction Act that allows the government to negotiate lower prices for certain high-cost prescription drugs.

PhRMA had argued that the program was unconstitutional and infringed upon the rights of drugmakers. However, the three-judge panel affirmed a lower court's decision, concluding that pharmaceutical companies are not entitled to sell their products to Medicare at prices of their own choosing. The court’s decision effectively maintains the government's authority to proceed with these negotiations as intended by the legislation.

This ruling marks a significant victory for the Biden administration, which has championed the program as a necessary measure to lower healthcare costs for seniors and reduce federal spending. While the pharmaceutical industry has consistently argued that such price controls stifle innovation and limit research into new medical treatments, the court found that the government’s role in negotiating prices within a voluntary federal program does not violate existing constitutional protections for private businesses. It remains to be seen whether PhRMA will seek further appeals or pursue alternative legal strategies to challenge the program in other jurisdictions.